The bulletin of the Yamaguchi Medical School

Continued by:Medical Science & Innovation
EISSN:2758-5441

Back to Top

The bulletin of the Yamaguchi Medical School Volume 65 Issue 1-2
published_at 2018

Immunoglobulin-resistant kawasaki disease associated with human parvovirus B19 infection

Immunoglobulin-resistant kawasaki disease associated with human parvovirus B19 infection
Korenaga Yuno
Okada Seigo
Hirano Reiji
Ohga Shouichi
fulltext
901 KB
A050065000103.pdf
Descriptions
A 23-month-old female presented with 6 full symptoms of Kawasaki disease (KD) and thrombocytopenic purpura of the lower extremities. Repeated intravenous immunoglobulin normalized the platelet counts, but not improved the activity of intractable KD. Primary infection of human parvovirus B19 (B19V) was determined at the diagnosis of KD based on the hypocomplementemia and the positive tests for anti-B19V IgM antibody. Infliximab therapy led to the complete resolution with no atypical or persistent infection of B19V, or coronary artery lesions. This is the first report of intravenous immunoglobulin-resistant KD associated with the primary infection of B19V. Successful treatment of the B19V-associated KD case suggested a clinical utility of the standard rescue infliximab for the treatment of intravenous immunoglobulin-resistant KD, possibly with concurrent infection. Abbreviations: B19V: human parvovirus B19, IVIG: ntravenous immunoglobulin, KD: Kawasaki disease
Creator Keywords
infliximab
Kawasaki disease
parvovirus B19
virus reactivation